JNJ-67571244

· Janssen Research & Development, LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for JNJ-67571244, covering 2025-05-23 to 2025-05-23. Get the full timeline:

Most recent: Clinical Trial Update: A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) [Phase 1]

See pricing